Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All remdesivir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ 5 or 10 day remdesivir vs... 35% Improvement Relative Risk Remdesivir  Spinner et al.  LATE TREATMENT  RCT Is late treatment with remdesivir beneficial for COVID-19? RCT 584 patients in multiple countries (March - April 2020) Lower mortality with remdesivir (not stat. sig., p=0.5) c19early.org Spinner et al., JAMA, August 2020 Favors remdesivir Favors control

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19A Randomized Clinical Trial

Spinner et al., JAMA, doi:10.1001/jama.2020.16349
Aug 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Late stage (median 8 days from symptom onset) RCT 584 patients with moderate COVID-19 showing (non-statistically significant) lower mortality.
5-day remdesivir had significantly higher odds of a better clinical status distribution on the 7-point ordinal scale, odds ratio OR 1.65, p = 0.02. The difference for 10-day remdesivir was not statistically significant, p=0.18.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
5 or 10 day remdesivir vs. control 28 day mortality, 34.9% lower, RR 0.65, p = 0.50, treatment 5 of 384 (1.3%), control 4 of 200 (2.0%), NNT 143, day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Spinner et al., 21 Aug 2020, Randomized Controlled Trial, multiple countries, peer-reviewed, 30 authors, study period 15 March, 2020 - 18 April, 2020, average treatment delay 8.0 days.
This PaperRemdesivirAll
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
MD Christoph D Spinner, MD Robert L Gottlieb, PhD Gerard J Criner, José Ramón Arribas López, MD Anna Maria Cattelan, MD Alex Soriano Viladomiu, MD Onyema Ogbuagu, MD Prashant Malhotra, DO; Kathleen M Mullane, MD Antonella Castagna, Louis Yi Ann Chai, MD Meta Roestenberg, Owen Tak Yin Tsang, MD Enos Bernasconi, MD; Paul Le Turnier, MD Shan-Chwen Chang, MD Devi Sengupta, DPhil Robert H Hyland, MD Anu O Osinusi, MD Huyen Cao, MS Christiana Blair, PhD Hongyuan Wang, MD, PhD; Anuj Gaggar, MD Diana M Brainard, MD Mark J Mcphail, MD Sanjay Bhagani, MD Mi Young Ahn, MD Arun J Sanyal, MD; Gregory Huhn, MD Francisco M Marty
JAMA, doi:10.1001/jama.2020.16349
IMPORTANCE Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown. OBJECTIVE To determine the efficacy of 5 or 10 days of remdesivir treatment compared with standard care on clinical status on day 11 after initiation of treatment. DESIGN, SETTING, AND PARTICIPANTS Randomized, open-label trial of hospitalized patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and moderate COVID-19 pneumonia (pulmonary infiltrates and room-air oxygen saturation >94%) enrolled from March 15 through April 18, 2020, at 105 hospitals in the United States, Europe, and Asia. The date of final follow-up was May 20, 2020. INTERVENTIONS Patients were randomized in a 1:1:1 ratio to receive a 10-day course of remdesivir (n = 197), a 5-day course of remdesivir (n = 199), or standard care (n = 200). Remdesivir was dosed intravenously at 200 mg on day 1 followed by 100 mg/d. MAIN OUTCOMES AND MEASURES The primary end point was clinical status on day 11 on a 7-point ordinal scale ranging from death (category 1) to discharged (category 7). Differences between remdesivir treatment groups and standard care were calculated using proportional odds models and expressed as odds ratios. An odds ratio greater than 1 indicates difference in clinical status distribution toward category 7 for the remdesivir group vs the standard care group. RESULTS Among 596 patients who were randomized, 584 began the study and received remdesivir or continued standard care (median age, 57 [interquartile range, 46-66] years; 227 [39%] women; 56% had cardiovascular disease, 42% hypertension, and 40% diabetes), and 533 (91%) completed the trial. Median length of treatment was 5 days for patients in the 5-day remdesivir group and 6 days for patients in the 10-day remdesivir group. On day 11, patients in the 5-day remdesivir group had statistically significantly higher odds of a better clinical status distribution than those receiving standard care (odds ratio, 1.65; 95% CI, 1.09-2.48; P = .02). The clinical status distribution on day 11 between the 10-day remdesivir and standard care groups was not significantly different (P = .18 by Wilcoxon rank sum test). By day 28, 9 patients had died: 2 (1%) in the 5-day remdesivir group, 3 (2%) in the 10-day remdesivir group, and 4 (2%) in the standard care group. Nausea (10% vs 3%), hypokalemia (6% vs 2%), and headache (5% vs 3%) were more frequent among remdesivir-treated patients compared with standard care. CONCLUSIONS AND RELEVANCE Among patients with moderate COVID-19, those randomized to a 10-day course of remdesivir did not have a statistically significant difference in clinical status compared with standard care at 11 days after initiation of treatment. Patients randomized to a 5-day course of remdesivir had a statistically significant difference in clinical status compared with..
ARTICLE INFORMATION Accepted for Publication: August 12, receiving grants from Galectin and Bristol-Myers; consulting for Conatus, Gilead, Pfizer, Boehringer Ingelheim, Merck, Hemoshear, Lilly, Novo Nordisk, Ardelyx, Terns, ENYO, Birdrock, Albireo, Sanofi, Janssen, Takeda, Zydus, AMRA, Poxel, Servier, Second Genome, and General Electric; receiving grants and consulting for Mallinckrodt, Salix, Novartis, and Nimbus; being principal investigator of an ongoing trial for Genfit; receiving grants and being principal investigator of an ongoing trial for Immuron; receiving grants, consulting for, and being principal investigator of ongoing trials for Echosens-Sandill and Sequana; providing advice but receiving no personal remuneration for Intercept, Galectin, Fractyl, Durect, Indalo, Allergan, Chemomab, Affimmune, Teva, BASF, Perspectum, and 89bio; and being the inventor for a patent held jointly by OWL and Virginia Commonwealth University. Dr Huhn reported that his institution received grants from Gilead, GlaxoSmithKline/ViiV, Janssen, Bristol-Meyers Squibb, Proteus, Lilly, and the National Institute of Allergy and Infectious Diseases and that he received consulting fees from Gilead, ViiV, Janssen, and Theratechnologies. Dr Marty reported receipt of grants from Ansun, Chimerix, Gilead, and Merck and personal fees from AlloVir, Janssen, Kyorin, Merck, ReViral, and Symbio. Drs SenGupta, Hyland, Osinusi, Cao, Blair, Wang, Gaggar, and Brainard are employees of and own stock in Gilead..
References
Beigel, Tomashek, Dodd, ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19-preliminary report, N Engl J Med. Published online, doi:10.1056/NEJMoa2007764
Cohen, Hall, John, Rapoport, The early natural history of SARS-CoV-2 infection: clinical observations from an urban, ambulatory COVID-19 clinic, Mayo Clin Proc, doi:10.1016/j.mayocp.2020.04.010
Cummings, Baldwin, Abrams, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet, doi:10.1016/S0140-6736(20)31189-2
Goldman, Lye, Hui, -540-5773 Investigators. Remdesivir for 5 or 10 days in patients with severe Covid-19, N Engl J Med. Published online, doi:10.1056/NEJMoa2015301
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with Covid-19-preliminary report, N Engl J Med. Published online, doi:10.1056/NEJMoa20201436
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Peterson, Vock, Powers, Analysis of an ordinal end point for use in evaluating treatments for severe influenza requiring hospitalization, Clin Trials, doi:10.1177/1740774517697919
Pizzorno, Padey, Dubois, In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2, Antiviral Res, doi:10.1016/j.antiviral.2020.104878
Richardson, Hirsch, Narasimhan, Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA, doi:10.1001/jama.2020.6775?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2020.16349
Sheahan, Sims, Graham, Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, Sci Transl Med, doi:10.1126/scitranslmed.aal3653
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Williamson, Feldmann, Schwarz, Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2, Nature, doi:10.1038/s41586-020-2423-5
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2020.16349
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Zhu, Zhang, Wang, China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, doi:10.1056/NEJMoa2001017
{ 'DOI': '10.1001/jama.2020.16349', 'ISSN': ['0098-7484'], 'URL': 'http://dx.doi.org/10.1001/jama.2020.16349', 'author': [ { 'affiliation': [ { 'name': 'Technical University of Munich, School of Medicine, University ' 'Hospital Rechts der Isar, Munich, Germany'}], 'family': 'Spinner', 'given': 'Christoph D.', 'sequence': 'first'}, { 'affiliation': [{'name': 'Baylor University Medical Center, Dallas, Texas'}], 'family': 'Gottlieb', 'given': 'Robert L.', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Lewis Katz School of Medicine at Temple University, ' 'Philadelphia, Pennsylvania'}], 'family': 'Criner', 'given': 'Gerard J.', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Instituto de Investigación Hospital Universitario La Paz, ' 'Madrid, Spain'}], 'family': 'Arribas López', 'given': 'José Ramón', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Azienda Ospedaliera di Padova, Padova, Italy'}], 'family': 'Cattelan', 'given': 'Anna Maria', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain'}], 'family': 'Soriano Viladomiu', 'given': 'Alex', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Yale School of Medicine, New Haven, Connecticut'}], 'family': 'Ogbuagu', 'given': 'Onyema', 'sequence': 'additional'}, { 'affiliation': [{'name': 'North Shore University Hospital, Manhasset, New York'}], 'family': 'Malhotra', 'given': 'Prashant', 'sequence': 'additional'}, { 'affiliation': [{'name': 'University of Chicago, Chicago, Illinois'}], 'family': 'Mullane', 'given': 'Kathleen M.', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'IRCCS San Raffaele Hospital and Vita-Salute San Raffaele ' 'University, Milan, Italy'}], 'family': 'Castagna', 'given': 'Antonella', 'sequence': 'additional'}, { 'affiliation': [{'name': 'National University Health System, Singapore'}], 'family': 'Chai', 'given': 'Louis Yi Ann', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Leiden University Medical Center, Leiden, the Netherlands'}], 'family': 'Roestenberg', 'given': 'Meta', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Princess Margaret Hospital, Hong Kong, China'}], 'family': 'Tsang', 'given': 'Owen Tak Yin', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Ente Ospedaliero Cantonale, Bellinzona, Switzerland'}], 'family': 'Bernasconi', 'given': 'Enos', 'sequence': 'additional'}, { 'affiliation': [{'name': 'University of Nantes, Nantes, France'}], 'family': 'Le Turnier', 'given': 'Paul', 'sequence': 'additional'}, { 'affiliation': [{'name': 'National Taiwan University Hospital, Taipei, Taiwan'}], 'family': 'Chang', 'given': 'Shan-Chwen', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Gilead Sciences, Foster City, California'}], 'family': 'SenGupta', 'given': 'Devi', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Gilead Sciences, Foster City, California'}], 'family': 'Hyland', 'given': 'Robert H.', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Gilead Sciences, Foster City, California'}], 'family': 'Osinusi', 'given': 'Anu O.', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Gilead Sciences, Foster City, California'}], 'family': 'Cao', 'given': 'Huyen', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Gilead Sciences, Foster City, California'}], 'family': 'Blair', 'given': 'Christiana', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Gilead Sciences, Foster City, California'}], 'family': 'Wang', 'given': 'Hongyuan', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Gilead Sciences, Foster City, California'}], 'family': 'Gaggar', 'given': 'Anuj', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Gilead Sciences, Foster City, California'}], 'family': 'Brainard', 'given': 'Diana M.', 'sequence': 'additional'}, { 'affiliation': [{'name': 'King’s College, London, England'}], 'family': 'McPhail', 'given': 'Mark J.', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Royal Free Hospital, London, England'}], 'family': 'Bhagani', 'given': 'Sanjay', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Seoul Medical Center, Seoul, South Korea'}], 'family': 'Ahn', 'given': 'Mi Young', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Virginia Commonwealth University, Richmond'}], 'family': 'Sanyal', 'given': 'Arun J.', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Cook County Health, Chicago, Illinois'}], 'family': 'Huhn', 'given': 'Gregory', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Brigham and Women’s Hospital and Harvard Medical School, Boston, ' 'Massachusetts'}], 'family': 'Marty', 'given': 'Francisco M.', 'sequence': 'additional'}, {'affiliation': [], 'name': 'for the GS-US-540-5774 Investigators', 'sequence': 'additional'}], 'container-title': 'JAMA', 'container-title-short': 'JAMA', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2020, 8, 21]], 'date-time': '2020-08-21T15:31:30Z', 'timestamp': 1598023890000}, 'deposited': { 'date-parts': [[2020, 9, 15]], 'date-time': '2020-09-15T15:03:21Z', 'timestamp': 1600182201000}, 'indexed': {'date-parts': [[2024, 4, 9]], 'date-time': '2024-04-09T12:35:31Z', 'timestamp': 1712666131141}, 'is-referenced-by-count': 964, 'issue': '11', 'issued': {'date-parts': [[2020, 9, 15]]}, 'journal-issue': {'issue': '11', 'published-print': {'date-parts': [[2020, 9, 15]]}}, 'language': 'en', 'link': [ { 'URL': 'https://jamanetwork.com/journals/jama/articlepdf/2769871/jama_spinner_2020_oi_200097_1600070022.50408.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '10', 'original-title': [], 'page': '1048', 'prefix': '10.1001', 'published': {'date-parts': [[2020, 9, 15]]}, 'published-print': {'date-parts': [[2020, 9, 15]]}, 'publisher': 'American Medical Association (AMA)', 'reference': [ { 'DOI': '10.1016/j.mayocp.2020.04.010', 'article-title': 'The early natural history of SARS-CoV-2 infection: clinical ' 'observations from an urban, ambulatory COVID-19 clinic.', 'author': 'Cohen', 'doi-asserted-by': 'publisher', 'first-page': '1124', 'issue': '6', 'journal-title': 'Mayo Clin Proc', 'key': 'joi200097r3', 'volume': '95', 'year': '2020'}, { 'DOI': '10.1001/jama.2020.2648', 'article-title': 'Characteristics of and important lessons from the coronavirus disease ' '2019 (COVID-19) outbreak in China: summary of a report of 72?314 cases ' 'from the Chinese Center for Disease Control and Prevention.', 'author': 'Wu', 'doi-asserted-by': 'publisher', 'first-page': '1239', 'issue': '13', 'journal-title': 'JAMA', 'key': 'joi200097r4', 'volume': '323', 'year': '2020'}, { 'DOI': '10.1016/S0140-6736(20)30566-3', 'article-title': 'Clinical course and risk factors for mortality of adult inpatients with ' 'COVID-19 in Wuhan, China: a retrospective cohort study.', 'author': 'Zhou', 'doi-asserted-by': 'publisher', 'first-page': '1054', 'issue': '10229', 'journal-title': 'Lancet', 'key': 'joi200097r5', 'volume': '395', 'year': '2020'}, { 'DOI': '10.1016/S0140-6736(20)31189-2', 'article-title': 'Epidemiology, clinical course, and outcomes of critically ill adults ' 'with COVID-19 in New York City: a prospective cohort study.', 'author': 'Cummings', 'doi-asserted-by': 'publisher', 'first-page': '1763', 'issue': '10239', 'journal-title': 'Lancet', 'key': 'joi200097r6', 'volume': '395', 'year': '2020'}, { 'DOI': '10.1126/scitranslmed.aal3653', 'article-title': 'Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic ' 'coronaviruses.', 'author': 'Sheahan', 'doi-asserted-by': 'crossref', 'issue': '396', 'journal-title': 'Sci Transl Med', 'key': 'joi200097r7', 'volume': '9', 'year': '2017'}, { 'DOI': '10.1016/j.antiviral.2020.104878', 'article-title': 'In vitro evaluation of antiviral activity of single and combined ' 'repurposable drugs against SARS-CoV-2.', 'author': 'Pizzorno', 'doi-asserted-by': 'crossref', 'journal-title': 'Antiviral Res', 'key': 'joi200097r8', 'year': '2020'}, { 'article-title': 'Clinical benefit of remdesivir in rhesus macaques infected with ' 'SARS-CoV-2.', 'author': 'Williamson', 'journal-title': 'Nature', 'key': 'joi200097r9'}, { 'DOI': '10.1016/S0140-6736(20)31022-9', 'article-title': 'Remdesivir in adults with severe COVID-19: a randomised, double-blind, ' 'placebo-controlled, multicentre trial.', 'author': 'Wang', 'doi-asserted-by': 'publisher', 'first-page': '1569', 'issue': '10236', 'journal-title': 'Lancet', 'key': 'joi200097r10', 'volume': '395', 'year': '2020'}, { 'article-title': 'Remdesivir for the treatment of Covid-19—preliminary report.', 'author': 'Beigel', 'journal-title': 'N Engl J Med', 'key': 'joi200097r11'}, { 'article-title': 'Remdesivir for 5 or 10 days in patients with severe Covid-19.', 'author': 'Goldman', 'journal-title': 'N Engl J Med', 'key': 'joi200097r12'}, { 'DOI': '10.1001/jama.2013.281053', 'article-title': 'World Medical Association Declaration of Helsinki: ethical principles ' 'for medical research involving human subjects.', 'author': 'World Medical Association', 'doi-asserted-by': 'publisher', 'first-page': '2191', 'issue': '20', 'journal-title': 'JAMA', 'key': 'joi200097r15', 'volume': '310', 'year': '2013'}, { 'DOI': '10.1177/1740774517697919', 'article-title': 'Analysis of an ordinal end point for use in evaluating treatments for ' 'severe influenza requiring hospitalization.', 'author': 'Peterson', 'doi-asserted-by': 'publisher', 'first-page': '264', 'issue': '3', 'journal-title': 'Clin Trials', 'key': 'joi200097r16', 'volume': '14', 'year': '2017'}, { 'article-title': 'Dexamethasone in hospitalized patients with Covid-19—preliminary ' 'report.', 'author': 'Horby', 'journal-title': 'N Engl J Med', 'key': 'joi200097r17'}, { 'DOI': '10.1001/jama.2020.6775', 'article-title': 'Presenting characteristics, comorbidities, and outcomes among 5700 ' 'patients hospitalized with COVID-19 in the New York City area.', 'author': 'Richardson', 'doi-asserted-by': 'publisher', 'first-page': '2052', 'issue': '20', 'journal-title': 'JAMA', 'key': 'joi200097r18', 'volume': '323', 'year': '2020'}, { 'DOI': '10.1016/S0140-6736(20)30183-5', 'article-title': 'Clinical features of patients infected with 2019 novel coronavirus in ' 'Wuhan, China.', 'author': 'Huang', 'doi-asserted-by': 'publisher', 'first-page': '497', 'issue': '10223', 'journal-title': 'Lancet', 'key': 'joi200097r19', 'volume': '395', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2001017', 'article-title': 'A novel coronavirus from patients with pneumonia in China, 2019.', 'author': 'Zhu', 'doi-asserted-by': 'publisher', 'first-page': '727', 'issue': '8', 'journal-title': 'N Engl J Med', 'key': 'joi200097r20', 'volume': '382', 'year': '2020'}, { 'key': 'joi200097r1', 'unstructured': 'World Health Organization. Coronavirus Disease (COVID-19) Situation ' 'Report—202. Published August 9, 2020. Accessed August 10, 2020. ' 'https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200809-covid-19-sitrep-202.pdf'}, { 'key': 'joi200097r2', 'unstructured': 'Johns Hopkins Coronavirus Resource Center. Accessed August 10, 2020. ' 'https://coronavirus.jhu.edu/map.html'}, { 'key': 'joi200097r13', 'unstructured': 'US Food and Drug Administration. Coronavirus (COVID-19) update: FDA ' 'issues emergency use authorization for potential COVID-19 treatment. ' 'Published May 1, 2020. Accessed August 10, 2020. ' 'https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment'}, { 'key': 'joi200097r14', 'unstructured': 'European Medicines Agency. First COVID-19 treatment recommended for EU ' 'authorization. Published June 25, 2020. Accessed August 10, 2020. ' 'https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation'}, { 'key': 'joi200097r21', 'unstructured': 'World Health Organization. COVID-19 Therapeutic Trial Synopsis. ' 'Published February 18, 2020. Accessed 24 July 2020. ' 'http://www.who.int/publications-detail/covid-19-therapeutic-trial-synopsis'}], 'reference-count': 21, 'references-count': 21, 'relation': { 'has-review': [ { 'asserted-by': 'object', 'id': '10.3410/f.738527140.793578651', 'id-type': 'doi'}]}, 'resource': {'primary': {'URL': 'https://jamanetwork.com/journals/jama/fullarticle/2769871'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['General Medicine'], 'subtitle': ['A Randomized Clinical Trial'], 'title': 'Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate ' 'COVID-19', 'type': 'journal-article', 'volume': '324'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit